|
A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma Clinical research trials and A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma. A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma clinical trial. Subjects frequently get the best healthcare possible for their A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma  A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma
A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma
For Condition: Hodgkin's Lymphoma,Lymphoma, Non-Hodgkin
Status: Recruiting
Sponsor(s): Abbott Laboratories ,
Synopsis: The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria A subject will be eligible for study participation if all of the following criteria are met: 1. The subject is at least 18 years of age. 2. The subject has histologically confirmed non-Hodgkin's Lymphoma (NHL) (excluding Burkitt's, Burkitt's type or HIV associated lymphoma) or Hodgkin's Lymphoma (HL) that is refractory to or has relapsed after standard therapy or for which there is no known effective treatment. 3. The subject must have measurable disease by the CHESON Criteria for Tumor Response. 4. The subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2. 5. The subject is able to self-administer or has a caregiver who can reliably administer subcutaneous injections. 6. The subject must have adequate bone marrow, renal and hepatic function as follows: Bone marrow: White blood cell count (WBC) greater than or equal to 3,000/mm3; Platelets greater than or equal to 75,000/mm3 unless subject has received a prior tranplant or bone marrow involvement with lymphoma has been documented; then platelets of equal to or greater than 50,000 is acceptable. Hemoglobin greater than or equal to 8.5 g/dL; ANC greater than or equal to 1000/mm3 Renal function: Serum creatinine less than or equal to 2.0 mg/dLHepatic function: AST and ALT less than or equal to 3.0 X ULN 7. The subject must not be pregnant or lactating and all subjects (male and female) must use a contraceptive method deemed appropriate by the investigator while in the study and up to two months following completion of therapy. 8. The subject has voluntarily signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent prior to any study specific procedures. Exclusion Criteria A subject will be ineligible for study participation if any of the following criteria are met: 1. The subject has a history of or currently exhibits Central Nervous System (CNS) metastasis. Brain MRI within 28 days of enrollment is required to confirm absence of CNS metastases. 2. The subject is receiving therapeutic anticoagulation therapy. Low dose anticoagulation (e.g., low dose Coumadin) for catheter prophylaxis is permitted; PT/PTT must be within normal limits. 3. The subject has a history of or currently exhibits clinically significant cancer related events of bleeding (e.g., hemoptysis). The subject has a recent history of (within 4 weeks of Study Day 1) or currently exhibits other clinically significant events of bleeding. 4. The subject has received any therapy for lymphoma including chemotherapy, antibody therapy, radiotherapy or any investigational therapy within four weeks prior to study drug administration. 5. The subject has been initiated on steroids or there is an increase in current steroid dose within three months prior to study drug administration. 6. The subject exhibits evidence of clinically significant uncontrolled condition(s) and/or is considered by the investigator to be unable to tolerate the proposed treatment or procedures. 7. The subject has history of other previous malignancies within 5 years, with the exception of: Adequately treated in situ carcinoma of the cervix uteriBasal or squamous cell carcinoma of the skin.
Total Enrollment:
Location and Contact Information:
Kansas City Oncology and Hematology Group *Recruiting*
Kansas City, Missouri, 64111
United States
Recruiting Vickie Thomas 816-531-2740
Arizona Clinical Research Center *Recruiting*
Tucson, Arizona, 85712
United States
Recruiting Patricia Plezia 520-290-2510
Oncology-Hematology Group of South Florida *Recruiting*
Miami, Florida, 33176
United States
Recruiting Julie Reed 305-595-2141
USC - Norris Cancer Center *Recruiting*
Los Angeles, California, 90033
United States
Recruiting Byron Espina 323-865-0371
U of W - Comprehensive Care Center *Recruiting*
Madison, Wisconsin, 53792
United States
Recruiting Nancy Turman 608-263-1974
Raleigh Hematology Oncology Clinic *Recruiting*
Cary, North Carolina, 27511
United States
Recruiting Diana Bracco 919-852-1994
MD Anderson Cancer Center *Not yet recruiting*
Houston, Texas, 77030
United States
Not yet recruiting Marilyn Clemens 713-792-3610
Albany Regional Cancer Center *Recruiting*
Albany, New York, 12208
United States
Recruiting Michele Butler 518-489-2607
Hematology Oncology Associates *Recruiting*
Phoenix, Arizona, 85012
United States
Recruiting Tina Cusick 602-277-4868
Arch Medical Services, INC. *Recruiting*
St. Louis, Missouri, 63142
United States
Recruiting Kelli Martin
Hematology Oncology Associates *Recruiting*
San Antonio, Texas, 78229
United States
Recruiting Annelies Burnley
The West Cancer Clinic *Recruiting*
Memphis, Tennessee, 38120
United States
Recruiting Marine Brotherton 901-683-0055
Cancer Centers of Florida, P.A. *Recruiting*
Orlando, Florida, 32806
United States
Recruiting Lynn Hogue 407-426-8484
The Center for Hematology-Oncology *Recruiting*
Boca Raton, Florida, 33486
United States
Recruiting Dolores Preiser 561-416-8869
Additional Information:
Study ID Numbers: M02-457;
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061672
Other Lymphoma, Non-Hodgkin Studies:
1. Meaning-Centered Psychotherapy in Advanced Cancer
2. Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas
3. Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
4. Proleukin in Combination with Rituxan in Patients with Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
5. Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin’s Lymphoma
Related Studies:
Other Lymphoma, Non-Hodgkin Clinical Trials
Other Arizona Clinical Trials
Other Phoenix Clinical Trials
A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma
|
|
|
|
|
|
|
|
